124 related articles for article (PubMed ID: 23069986)
1. New antidiabetic therapies: innovative strategies for an old problem.
Lehrke M; Marx N
Curr Opin Lipidol; 2012 Dec; 23(6):569-75. PubMed ID: 23069986
[TBL] [Abstract][Full Text] [Related]
2. Antidiabetic agents: past, present and future.
Mehanna A
Future Med Chem; 2013 Mar; 5(4):411-30. PubMed ID: 23495689
[TBL] [Abstract][Full Text] [Related]
3. GLP-1 based therapy for type 2 diabetes.
Arulmozhi DK; Portha B
Eur J Pharm Sci; 2006 May; 28(1-2):96-108. PubMed ID: 16488579
[TBL] [Abstract][Full Text] [Related]
4. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
5. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
6. Newly approved and promising antidiabetic agents.
Combettes M; Kargar C
Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
[TBL] [Abstract][Full Text] [Related]
7. Evolving therapeutic options for type 2 diabetes mellitus: an overview.
Guthrie RM
Postgrad Med; 2012 Nov; 124(6):82-9. PubMed ID: 23322141
[TBL] [Abstract][Full Text] [Related]
8. Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?
Nauck M; Smith U
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):513-23. PubMed ID: 19748068
[TBL] [Abstract][Full Text] [Related]
9. New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond.
Inzucchi SE; McGuire DK
Circulation; 2008 Jan; 117(4):574-84. PubMed ID: 18227398
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
Cavender MA; Lincoff AM
Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
[TBL] [Abstract][Full Text] [Related]
11. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.
Ahrén B; Schmitz O
Horm Metab Res; 2004; 36(11-12):867-76. PubMed ID: 15655721
[TBL] [Abstract][Full Text] [Related]
12. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
Holst JJ; McGill MA
Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 21958333
[TBL] [Abstract][Full Text] [Related]
13. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.
Ghosh RK; Ghosh SM; Chawla S; Jasdanwala SA
J Clin Pharmacol; 2012 Apr; 52(4):457-63. PubMed ID: 21543663
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs.
Panicker GK; Karnad DR; Salvi V; Kothari S
J Assoc Physicians India; 2012 Jan; 60():56-61. PubMed ID: 22715547
[TBL] [Abstract][Full Text] [Related]
15. [Oral antidiabetic agents: which role in 2006?].
Gasteyger C; Egli M
Rev Med Suisse; 2006 May; 2(68):1446-50, 1452. PubMed ID: 16783989
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms underlying the antiatherosclerotic and antidiabetic effects of probucol, succinobucol, and other probucol analogues.
Stocker R
Curr Opin Lipidol; 2009 Jun; 20(3):227-35. PubMed ID: 19373083
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
Tandon N; Ali MK; Narayan KM
Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
[TBL] [Abstract][Full Text] [Related]
18. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.
Havale SH; Pal M
Bioorg Med Chem; 2009 Mar; 17(5):1783-802. PubMed ID: 19217790
[TBL] [Abstract][Full Text] [Related]
19. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
Halimi S
Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapy of hyperglycemia.
Kulasa KM; Henry RR
Expert Opin Pharmacother; 2009 Oct; 10(15):2415-32. PubMed ID: 19743938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
